Active Clinical Research for Lung Cancer

Comprehensive Cancer Centers runs Phase II and Phase III research trials for the following lung cancers:

Hepatocellular Carcinoma (HCC)

Title: A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma
Study#: 14148 Phase: II
Contact Us: For information about this study, Email Us, or use our form field.

Non-Small Cell Lung Cancer

A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer (Keynote-604)
Study #: 16227
Phase: III
Local P.I.: Nguyen Sites: All sites
Contact Us: For information about this study, Email Us, or use our form field.

Title: A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PDL1 Antibody) Compared with Standard of Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1 Selected Patients with Completely Resected Non-Small Cell Lung Cancer
Study #: i2169 Phase: III
Contact Us: For information about this study, Email Us, or use our form field.

Title: A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Malignancies **COHORT B -contact BMS Trial Manager Lori Pagliaro for slots availability, COHORT C OPEN**
Study #: 16156 Phase: III
Contact Us: For information about this study, Email Us, or use our form field.

Title: A phase II, open label, non-randomised study of afatinib in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the lung **ON HOLD**
Study #: i2486 Phase: III
Contact Us: For information about this study, Email Us, or use our form field.

Title: A Phase II Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatment for Patients with Advanced or Metastatic NSCLC Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
Study #: 17030 Phase: II
Local P.I.: Dr. Brian Vicuna Sites: All
Contact Us: For information about this study, Email Us, or use our form field.

Click here to Email Us, or use our form field for updates on research efforts.